Protocol Ledger

NCT05475483 · Phase II · COMPLETED

Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

Interventional Phase II clinical trial protocol NCT05475483 sponsored by SOM Innovation Biotech SA in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-02 Enrollment: 139 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05475483
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)139 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05475483
Protocol FieldVerified Registry Value
NCT IdentifierNCT05475483
Consolidated Lead SponsorSOM Innovation Biotech SA
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment139 participants (ACTUAL)
Registered Start Date2022-08-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05475483
Hospital Research SiteLocationSite Profile
Charité Universitätsmedizin BerlinBerlin, GermanyOpen Hospital Dossier ->
Azienda Ospedaliera Universitaria Federico IINaples, ItalyOpen Hospital Dossier ->
Hospital de La Santa Creu I Sant PauBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI